The estimated Net Worth of Venture Management Co Iii L... is at least $4.02 Million dollars as of 25 June 2004. Venture L owns over 160,000 units of Momenta Pharmaceuticals stock worth over $4,022,487 and over the last 20 years Venture sold MNTA stock worth over $0.
Venture has made over 1 trades of the Momenta Pharmaceuticals stock since 2004, according to the Form 4 filled with the SEC. Most recently Venture bought 160,000 units of MNTA stock worth $1,040,000 on 25 June 2004.
The largest trade Venture's ever made was buying 160,000 units of Momenta Pharmaceuticals stock on 25 June 2004 worth over $1,040,000. On average, Venture trades about 160,000 units every 0 days since 2004. As of 25 June 2004 Venture still owns at least 76,648 units of Momenta Pharmaceuticals stock.
You can see the complete history of Venture L stock trades at the bottom of the page.
Over the last 20 years, insiders at Momenta Pharmaceuticals have traded over $110,027,424 worth of Momenta Pharmaceuticals stock and bought 827,300 units worth $5,505,611 . The most active insiders traders include Christoph H Westphal, Craig A Wheeler, and Peter Barrett. On average, Momenta Pharmaceuticals executives and independent directors trade stock every 6 days with the average trade being worth of $448,442. The most recent stock trade was executed by Ian Fier on 20 August 2020, trading 1,808 units of MNTA stock currently worth $94,323.
Momenta Pharmaceuticals, Inc. operates as a biotechnology company that focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases. Its products include the Glatiramer acetate injection and Enoxaparin Sodium injection. The company was founded by Ram Sasisekharan, Paul R. Schimmel, and Ganesh Venkatraman Kaundinya in May 2001 and is headquartered in Cambridge, MA.
Momenta Pharmaceuticals executives and other stock owners filed with the SEC include: